_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
The launch of the study was on the occasion of the International Day of Persons with Disabilities
Subscribe To Our Newsletter & Stay Updated
